派克

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Warby Parker(WRBY.US), With a Forecast Between $31 to $34
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Goldman Sachs Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $31
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• Goldman Sachs Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• A Quick Look at Today's Ratings for Warby Parker(WRBY.US), With a Forecast Between $27 to $33
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• BTIG Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Stifel Maintains Warby Parker(WRBY.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/20
• Piper Sandler Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY), Omada Health, Inc. (OMDA) and CAMP4 Therapeutics Corporation (CAMP)
  TipRanks · 2026/5/8
• 评级变动
  TD Cowen Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  William Blair Maintains Warby Parker(WRBY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• TD Cowen Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Telsey Advisory Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• 评级变动
  Citi Maintains Warby Parker(WRBY.US) With Hold Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/3/18
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA), Warby Parker (WRBY) and Aprea Therapeutics (APRE)
  TipRanks · 2026/8/13
• 评级变动
  BTIG Maintains Warby Parker(WRBY.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/5/1
• 评级变动
  TD Cowen Maintains Warby Parker(WRBY.US) With Buy Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/5/9
• 评级变动
  BofA Securities Initiates Warby Parker(WRBY.US) With Buy Rating, Announces Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/6/29
• 评级变动
  A Quick Look at Today's Ratings for Warby Parker(WRBY.US), With a Forecast Between $28 to $33
  \u5e02\u573a\u8d44\u8baf · 2026/8/7

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。